JP2023546383A5 - - Google Patents

Info

Publication number
JP2023546383A5
JP2023546383A5 JP2023521687A JP2023521687A JP2023546383A5 JP 2023546383 A5 JP2023546383 A5 JP 2023546383A5 JP 2023521687 A JP2023521687 A JP 2023521687A JP 2023521687 A JP2023521687 A JP 2023521687A JP 2023546383 A5 JP2023546383 A5 JP 2023546383A5
Authority
JP
Japan
Prior art keywords
annexin
ace2
composition
sequence
inhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546383A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/051422 external-priority patent/WO2022073134A1/en
Publication of JP2023546383A publication Critical patent/JP2023546383A/ja
Publication of JP2023546383A5 publication Critical patent/JP2023546383A5/ja
Pending legal-status Critical Current

Links

JP2023521687A 2020-10-09 2021-10-08 アネキシンａ５組成物及び方法 Pending JP2023546383A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089584P 2020-10-09 2020-10-09
US63/089,584 2020-10-09
PCT/CA2021/051422 WO2022073134A1 (en) 2020-10-09 2021-10-08 Annexin a5 compositions and methods

Publications (2)

Publication Number Publication Date
JP2023546383A JP2023546383A (ja) 2023-11-02
JP2023546383A5 true JP2023546383A5 (enExample) 2024-10-17

Family

ID=81126326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521687A Pending JP2023546383A (ja) 2020-10-09 2021-10-08 アネキシンａ５組成物及び方法

Country Status (4)

Country Link
US (1) US20230374091A1 (enExample)
JP (1) JP2023546383A (enExample)
CA (1) CA3198378A1 (enExample)
WO (1) WO2022073134A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129329A1 (en) * 2023-12-23 2025-06-26 London Health Sciences Centre Research Inc. Methods for treatment of sepsis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6843980B2 (en) * 2001-04-03 2005-01-18 Theseus Imaging, Corp. Methods for using annexin for detecting cell death in vivo and treating associated conditions
DE10145254A1 (de) * 2001-09-13 2003-04-10 November Ag Molekulare Medizin Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides
WO2010043045A1 (en) * 2008-10-17 2010-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
MX2023000226A (es) * 2020-07-09 2023-02-23 Exo Biologics Sa Proceso para la fabricacion de vesiculas extracelulares asociadas a proteinas.

Similar Documents

Publication Publication Date Title
Schuetz et al. Peptide and peptide-based inhibitors of SARS-CoV-2 entry
Heinrich et al. Nanomedicine strategies to target coronavirus
JP2023506765A5 (enExample)
JP2019531763A5 (enExample)
JP2009537143A5 (enExample)
JP2009504157A5 (enExample)
FI4074331T3 (fi) Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
JP2004115529A5 (enExample)
JP2010503396A5 (enExample)
JP2012523438A5 (enExample)
CA2817787C (en) Composition comprising a peptide and an inhibitor of viral neuraminidase
CN113072623B (zh) 一种靶向SARS-CoV-2 N蛋白的干扰肽的制备方法及应用
WO2022010938A3 (en) Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
US20240218059A1 (en) TGF-Beta 1 INHIBITORS FOR PREVENTING AND TREATING SARS-COV-2
JP2023542453A5 (enExample)
JP2024503091A5 (enExample)
F Nahhas et al. Nanoscale pathogens treated with nanomaterial-like peptides: a platform technology appropriate for future pandemics
Tanaka et al. A Crispr-Cas9 system designed to introduce point mutations into the human ACE2 gene to weaken the interaction of the ACE2 receptor with the SARS-CoV-2 S protein
WO2022094139A1 (en) Peptide inhibitors for the treatment and prevention of coronavirus infections
MX2022008748A (es) Administración oral de péptidos.
CN111163792A (zh) 用于治疗病毒感染的肽
CA3180858A1 (en) Peptides for the treatment of covid-19
JP2005506276A5 (enExample)
JOP20240271A1 (ar) ببتيدات إظهار أنشطة منع فقدان العضلات وتعزيز الكتلة العضلية واستخداماتها
WO2021228875A1 (en) Treatment of respiratory viral infections